基于构建卵巢癌类器官体模型基础上探讨erlotinib/HAPs治疗卵巢癌的新策略

卵巢癌是最致命的妇科癌症，化疗药物是不可或缺的重要治疗手段，但临床治疗中常出现耐药和药物治疗效果不佳，影响病人的生存率，如何建立有效评估药物疗效平台和开发新的治疗策略显得尤为重要。结合我们的工作和现有技术，我们提出一种全新的评价平台——体外类器官体模型及建立卵巢癌类器官体生物样品库。该模型最大程度地维持了肿瘤细胞在体内的特征，摒弃了以往单细胞系选择新药手段的不足，有助于开发个性化肿瘤治疗药物。同时基于前期研究发现和工作基础，我们提出erlotinib/HAPs联合抗卵巢癌治疗新策略的研究设想。本项目除对培养成功的类器官体进行生物学评估外，我们将利用该平台进行erlotinib/HAPs抗癌活性检测和分子机制研究，以填补顺铂耐药新的治疗手段。构建新的类器官体生物样品库将会成为卵巢癌肿瘤特性研究和新药物筛选的平台；联合erlotinib/HAPs抗卵巢新思路的提出和研发，具有重要的转化价值。

Ovarian cancer is the most deadly gynecological cancer. Chemotherapy is an indispensable and important treatment. However, the clinical treatment often results in drug resistance and poor effectivity of drug treatment, affecting the overall survival of patients. How to establish an effective platform for the evaluation of drug efficacy and the development of new treatment strategy seems particularly important. In combination with our work and existing technologies, we propose a new evaluation platform— in vitro organoid model and the living biobanks. The model can maximize the maintenance of tumor cells in the body characteristics, to abandon the past, the lack of means of selecting new drugs single cell line, and contribute to the development of personalized cancer treatment drugs. At the same time based on the previous findings and work, we propose combined anti-ovarian cancer treatment strategies of erlotinib / HAPs for the study. In addition to biological evaluation of successful organoid culture, we will use this platform to investigate the antitumor activity and molecular mechanisms of erlotinib / HAPs, and thus to complement the new therapeutic approaches for cisplatin resistance. The construction of a new organoid living biobanks will become a platform for the study of tumor hallmarks and screening of new drugs for ovarian cancer. The combination of erlotinib / HAPs and the development of new anti-ovarian strategies are of great value in translational medicine.